Among the S&P 500’s biggest fallers on Wednesday October 02 was Eli Lilly and Company (LLY). The stock experienced a 3.57% decline to $107.00 with 4.48 million shares changing hands.
Eli Lilly and Company started at an opening price of 110.33 and hit a high of $110.64 and a low of $106.66. Ultimately, the stock took a hit and finished the day at $3.96 per share. Eli Lilly and Company trades an average of n/a shares a day out of a total 965.43 million shares outstanding. The current moving averages are a 50-day SMA of $n/a and a 200-day SMA of $n/a. Eli Lilly and Company hit a high of $132.13 and a low of $104.17 over the last year.
Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly’s key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.
With its headquarters located in Indianapolis, IN, Eli Lilly and Company employs 38,680 people. After today’s trading, the company’s market cap has fallen to $103.3 billion, a P/S of n/a, a P/B of 37.15, and a P/FCF of n/a.
For all the attention paid to the Dow Jones Industrial Average (DJIA), it’s the S&P 500 that’s relied on by insiders and institutional investors. It represents the industry standard for American large-cap indices.
The Dow is made up of just 30 stocks to the S&P 500’s 500, and it uses an unreliable and outdated price-weighting system where the S&P 500 relies on market cap in weighting its returns. This is why its long-term returns is a much more reliable gauge for the performance of large- and mega-cap stocks over time.